Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Karyopharm Therapeutics Inc KPTI.OQ reported a quarterly adjusted loss of $2.77​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-4.80. The mean expectation of seven analysts for the quarter was for a loss of $4.18 per share. Wall Street expected results to range from $-4.56 to $-3.67 per share.

• Revenue fell 9.4% to $30.02 million from a year ago; analysts expected $35.24 million.

• Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of $2.77​.

• The company reported a quarterly loss of $23.46 million.

• Karyopharm Therapeutics Inc shares had risen by 60.7% this quarter and lost 40.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $55.00

This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)